Last reviewed · How we verify

Heilongjiang Quanle Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief

Heilongjiang Quanle Pharmaceutical Co., Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Compound Ciwujia Granules, Guipi Granules Compound Ciwujia Granules, Guipi Granules marketed Herbal combination / Traditional Chinese Medicine General wellness / Constitutional support

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Heilongjiang Quanle Pharmaceutical Co., Ltd.:

Cite this brief

Drug Landscape (2026). Heilongjiang Quanle Pharmaceutical Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/heilongjiang-quanle-pharmaceutical-co-ltd. Accessed 2026-05-17.

Related